arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ROCKET PHARMACEUTICALS, INC.

RCKT
$3.36 ▲ +0.08 (+2.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

ROCKET PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $379.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -11.9%
FCF / Share $-0.35
Trailing P/E 3.1x
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-47.59M
↑ +22.4%
FCF / Share Free cash flow per share
$-0.35
↑ +13.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Financial Health
12
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 51 quarters